For thyroid cancer cells resistant to 131I, low expression of MEG3 means increased expression of miR-182 and promotion of cell proliferation, which is detrimental to the treatment effect of 131I for thyroid cancer (Liu et al., 2018). The gene discussed is MEG3; the disease is thyroid cancer.